- Q1 2024 Calliditas Therapeutics AB Earnings Call TranscriptMay 23, 2024$22.75 (+4.79%)Earnings
- Q4 2023 Calliditas Therapeutics AB Earnings Call TranscriptFeb 21, 2024$20.3 (-2.96%)Earnings
- Q3 2023 Calliditas Therapeutics AB Earnings Call TranscriptNov 07, 2023$15.89 (-3.17%)Earnings
- Q2 2023 Calliditas Therapeutics AB Earnings Call TranscriptAug 17, 2023$15.9 (-16.09%)Earnings
- Q1 2023 Calliditas Therapeutics AB Earnings Call TranscriptMay 16, 2023$21.17 (-16.98%)Earnings
- Calliditas Therapeutics AB Nefigard Topline Data Presentation TranscriptMar 13, 2023
- Q4 2022 Calliditas Therapeutics AB Earnings Call TranscriptFeb 23, 2023$19.99 (+11.06%)Earnings
- Calliditas Therapeutics AB Fireside Chat with Everest Medicines Ltd TranscriptDec 14, 2022
- Q3 2022 Calliditas Therapeutics AB Earnings Call TranscriptNov 14, 2022$15 (-1.64%)Earnings
- Calliditas Therapeutics AB KOL Webinar TranscriptNov 08, 2022
- Q2 2022 Calliditas Therapeutics AB Earnings Call TranscriptAug 18, 2022$18 (-15.13%)Earnings
- Q1 2022 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2022$15.99 (+5.20%)Earnings
- Q4 2021 Calliditas Therapeutics AB Earnings Call TranscriptFeb 24, 2022$17.91 (+1.13%)Earnings
- Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy TranscriptDec 16, 2021
- Q3 2021 Calliditas Therapeutics AB Earnings Call TranscriptNov 18, 2021$17.7 (+6.88%)Earnings
- Q2 2021 Calliditas Therapeutics AB Earnings Call TranscriptAug 19, 2021$21.91 (-0.45%)Earnings
- Q1 2021 Calliditas Therapeutics AB Earnings Call TranscriptMay 18, 2021$29.08 (-0.14%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptMar 10, 2021
- Q4 2020 Calliditas Therapeutics AB Earnings Call TranscriptFeb 18, 2021$30.3 (-5.02%)Earnings
- Calliditas Therapeutics AB Corporate Analyst Meeting TranscriptJan 20, 2021
- Q3 2020 Calliditas Therapeutics AB Earnings Call TranscriptNov 12, 2020$32.7 (-2.39%)Earnings
- Calliditas Therapeutics AB (publ) - Special Call TranscriptNov 09, 2020
- Q2 2020 Calliditas Therapeutics AB Earnings Call TranscriptAug 13, 2020$22.03 (-4.47%)Earnings
- Q1 2020 Calliditas Therapeutics AB Earnings Call TranscriptMay 14, 2020Earnings
Q1 2024 Calliditas Therapeutics AB Earnings Call Transcript
Welcome to this Q1 2024 report from Calliditas Therapeutics. My name is Renee Aguiar-Lucander. I'm the CEO of the company, and I'm today joined by Fredrik Johansson, our Chief Financial Officer; Richard Philipson, our Chief Medical Officer; and Maria Tornsen, our President of North America. Next page please.
I would like to draw your attention to the disclaimer notice which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended and I refer to public filings including those containing risk factors. Next page, please.
So I would like to take you through some of our Q1 highlights, which included the appointment of Maria Tornsen as President of North America, who brings over 10 years of rare disease experience to Calliditas including multiple product launches, both in the US and ex-US.
Following our full approval in December last year, we were able to roll out new marketing materials to a fully trained field team in February,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)